ASTELLAS PHARMA US, INC.

Issues related to Medicare Part D and prescription drug pricing and patient access, including monitor implementation of related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169), including provisions in Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries. Issues related to pharmacy benefit manager transparency, including related provisions in S. 2973, the Modernizing and Ensuring PBM Accountability Act, H.R. 5378, the Lower Costs, More Transparency Act, H.R. 4822, the Health Care Price Transparency Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act, including provisions to establish new requirements for PBMs in Medicare Part D; and H.R. 5385, the Medicare PBM Accountability Act, including provisions to enhance PBM reporting requirements and reporting drug pricing information to HHS.

Support H. Res. 806, expressing support for the recognition of October 2023, as "World Menopause Awareness Month" and expressing the sense of the House of Representatives regarding global awareness and access to care during the menopausal transition and post-menopause.